SYBX Share Price | Synlogic, Inc. Stock Analysis & Recommendation

Q: How big is Synlogic, Inc.?

Market Cap: As of Jun 18, Synlogic, Inc. has a market capitalization of 14.50 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, Synlogic, Inc. reported net sales of 0.00 million and a net profit of 1.50 million.Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 12.75 million and total assets of 19.83 million.

Q: What does Synlogic, Inc. do?

Overview:Synlogic, Inc. is engaged in the development of Synthetic Biotic medicines for the treatment of rare genetic diseases and other conditions within the Pharmaceuticals & Biotechnology industry, operating in the micro-cap market.Financial Snapshot:- Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025)- Market-cap: USD 14.50 Million (Micro Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -1.32- Return on Equity: -38.28%- Price to Book: 1.11Contact Details:- Address: 301 Binney St Ste 402, CAMBRIDGE MA: 02142-1030- Tel: 1 617 4019975- Website: https://www.synlogictx.com/

Q: Is Synlogic, Inc. overvalued or undervalued?

As of 6 March 2025, Synlogic, Inc. has moved from a grade of risky to does not qualify, indicating a significant downgrade in its valuation outlook. The company is currently assessed as overvalued given its financial metrics, including a Price to Book Value of 1.08, an EV to EBIT of 0.51, and an ROCE of 145.50%, despite reporting a negative ROE of -38.28%. In comparison to its peers, Synlogic is positioned unfavorably against Poseida Therapeutics, Inc., which has a P/E of -15.24, and Xeris Biopharma Holdings, Inc., with a P/E of -15.77, both of which are also categorized as risky. The company's recent stock performance has underperformed the S&P 500, with a year-to-date return of -16.43% compared to the S&P 500's 2.44%. This combination of factors suggests that Synlogic, Inc. is overvalued in the current market environment.

Q: Is Synlogic, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Synlogic, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages are also bullish. However, the monthly Dow Theory remains bearish, and the OBV shows mild bearishness on a monthly basis. In terms of performance, Synlogic has outperformed the S&P 500 in the past week (13.61% vs. 1.05%) and the past month (16.78% vs. 2.33%), but it has significantly underperformed over longer periods, particularly in the 3-year and 5-year returns. Overall, the current stance is bullish, but with some mixed signals in the longer-term indicators.

Results Declared: Synlogic, Inc. has declared results on 12 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

100

Shareholding (Dec 2025)

FII

0.25%

Held by 5 FIIs

DII

70.52%

Held by 5 DIIs

Promoter

25.10%

How big is Synlogic, Inc.?

22-Jun-2025

As of Jun 18, Synlogic, Inc. has a market capitalization of 14.50 million, categorizing it as a Micro Cap company, with shareholder's funds of 12.75 million and total assets of 19.83 million as of December 2024.

View full answer

What does Synlogic, Inc. do?

22-Jun-2025

Synlogic, Inc. develops Synthetic Biotic medicines for rare genetic diseases and operates in the micro-cap Pharmaceuticals & Biotechnology sector, with a market cap of $14.50 million. The company is currently loss-making, with no dividend yield and negative return on equity.

View full answer

Who are in the management team of Synlogic, Inc.?

22-Jun-2025

As of March 2022, the management team of Synlogic, Inc. includes Dr. Peter Barrett (Independent Chairman), Dr. Aoife Brennan (CEO), and several independent directors: Mr. Michael Heffernan, Dr. Michael Burgess, Dr. Patricia Hurter, Mr. Chau Khuong, and Mr. Nick Leschly. They oversee the company's strategic direction and operations.

View full answer

Is Synlogic, Inc. overvalued or undervalued?

25-Jun-2025

As of March 6, 2025, Synlogic, Inc. is considered overvalued and has been downgraded to "does not qualify" due to unfavorable financial metrics and poor stock performance compared to its peers and the S&P 500.

View full answer

Is Synlogic, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Synlogic, Inc. shows a bullish trend with positive momentum indicators, though it has underperformed in the long term despite recent outperformance against the S&P 500.

View full answer

Compare Synlogic, Inc. with Similar Stocks

Lineage Cell Therapeutics, Inc.Verastem, Inc.Poseida Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 7 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.51

Return on Equity

-29.99%

Price to Book

0.68

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-40.09%

6 Months

-58.79%

1 Year

-46.89%

2 Years

-61.06%

3 Years

21.89%

4 Years

-98.15%

5 Years

-98.8%

Synlogic, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

14.11%

EBIT to Interest (avg)

-48.81

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.32

Sales to Capital Employed (avg)

0.10

Tax Ratio

0.33%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

60.61%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.68

EV to EBIT

2.22

EV to EBITDA

2.22

EV to Capital Employed

1.63

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

73.36%

ROE (Latest)

-29.99%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 3 Schemes (4.12%)

Foreign Institutions

Held by 5 Foreign Institutions (0.25%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 165.22% vs -360.00% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.10",
          "val2": "-0.80",
          "chgp": "-37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.40",
          "val2": "-1.60",
          "chgp": "250.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.50",
          "val2": "-2.30",
          "chgp": "165.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 95.73% vs 61.83% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.50",
          "val2": "-14.50",
          "chgp": "75.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.80",
          "val2": "-9.00",
          "chgp": "120.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "-23.40",
          "chgp": "95.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-1,972,125.00%",
          "chgp": "1,97,212.50%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.10

-0.80

-37.50%

Interest

0.00

Exceptional Items

2.40

-1.60

250.00%

Consolidate Net Profit

1.50

-2.30

165.22%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 165.22% vs -360.00% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.50

-14.50

75.86%

Interest

0.00

Exceptional Items

1.80

-9.00

120.00%

Consolidate Net Profit

-1.00

-23.40

95.73%

Operating Profit Margin (Excl OI)

0.00%

-1,972,125.00%

1,97,212.50%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 95.73% vs 61.83% in Dec 2024

All Annual Results

Company CV

About Synlogic, Inc.

Synlogic, Inc.

Pharmaceuticals & Biotechnology

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Company Coordinates

Company Details

301 Binney St Ste 402 , CAMBRIDGE MA : 02142-1030

Tel: 1 617 4019975

https://www.synlogictx.com/

Registrar Details